The broader market's underlying plumbing—from data center power grids to niche biotech pipelines—is seeing its most significant overhaul this year. According to people familiar with the matter, institutional attention is shifting toward companies securing long-term operational contracts, especially those tied to the AI boom. I'm told that several firms in this space are preparing structural updates before the next earnings cycle.

Solaris Energy Infrastructure (SEI.US)

Solaris has been riding the AI infrastructure wave, outperforming sector benchmarks this quarter. I'm told the company's recent expansion of its "Hatchbo" agreement—a massive 660 MW power plant specifically designed for AI workloads—is just the beginning. The company reported a 12% sequential bump in Q2 2026 total revenue to USD 219 million, with its power solutions unit jumping 23% to USD 158 million.

• Growth Pipeline: The August 2026 contract expansions are projected to add over USD 100 million in annual adjusted EBITDA.
• Dividends: The board just cleared a Q3 2026 dividend, paying out later this year.

Paysign (PAYS.US)

Paysign has staged a notable rally recently following a massive earnings beat. According to insiders, the fintech company is aggressively expanding its pharmaceutical patient affordability solutions, which surged 89% year-over-year in Q2 2026 to USD 14.6 million. Overall revenue hit a record USD 28.3 million, up 48.1%.

• Upgraded Guidance: Paysign raised its full-year 2026 revenue target to the USD 114 million to USD 117 million range.

GSI Technology (GSIT.US)

While GSI's core SRAM business is stabilizing—driving a 22.4% year-over-year revenue bump to USD 25.1 million in FY 2026—some analysts warn the stock's recent ascent may be overly dependent on unproven edge AI chips. The company posted an improved Q1 2026 loss of USD 0.13 per share, largely supported by defense sales.

Genprex (GNPX.US)

In the clinical stage, Genprex is executing a strategic pivot. I'm told the August 2026 biomarker assay partnership with Roche Diagnostics is a critical step for its REQORSA gene therapy. The company has seen a mixed performance this year as it works to spin off its GPX-002 diabetes asset into a new subsidiary.

Liminatus Pharma (LIMN.US)

Zero revenue hasn't stopped Liminatus from restructuring. The biopharma company, developing the IBA101 immune checkpoint inhibitor, moved to close its revised merger with InnocsAI LLC in early July 2026.

Also

• Lufax Holding (LU.US): The personal financial services platform is navigating a complex macro environment, holding an RMB 183.8 billion retail credit balance exiting 2025.
• WORK Medical Technology Group (WOK.US): The device maker continues to quietly supply Class I and II products across 30+ countries, with steady demand reported this year.
• UWM Holdings (UWMC.US): The wholesale mortgage lender remains a volume leader despite fluctuating rates in the housing sector.
• Embraer (EMBJ.US): Order backlogs in the aerospace sector continue to provide long-term visibility for the jet manufacturer.
• Select Sector SPDR Trust Communication Services (XLC.US): The communications sector ETF remains a key bellwether for media and telecom flows.

This article does not constitute investment advice.